Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Allopurinol and Febuxostat in APRT Deficiency
2021-002185-40Phase 4Completed
- Sponsor
- Landspitali
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of allopurinol and febuxostat in 2,8-dihydroxyadenine nephropathy (4 arms), sponsored by Landspitali. Primary endpoints: Urinary 2,8-dihydroxyadenine excretion and Plasma 2,8-dihydroxyadenine levels. Started Jul 2024; status: completed.
02
Drugs
allopurinolfebuxostat
03
Conditions
2,8-dihydroxyadenine nephropathy
Beyond the preview
Go deeper on 2021-002185-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002185-40.